• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Acute Spinal Cord Injury - Pipeline Review, H2 2012 Product Image

Acute Spinal Cord Injury - Pipeline Review, H2 2012

  • ID: 2298653
  • October 2012
  • 59 pages
  • Global Markets Direct

Acute Spinal Cord Injury – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Acute Spinal Cord Injury - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acute Spinal Cord Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury. Acute Spinal Cord Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Spinal Cord Injury.
- A review of the Acute Spinal Cord Injury products under development READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Acute Spinal Cord Injury Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Acute Spinal Cord Injury 8
Acute Spinal Cord Injury Therapeutics under Development by Companies 10
Acute Spinal Cord Injury Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Acute Spinal Cord Injury Therapeutics – Products under Development by Companies 15
Acute Spinal Cord Injury Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Acute Spinal Cord Injury Therapeutics Development 17
Novartis AG 17
Oxygen Biotherapeutics, Inc. 18
Proneuron Biotechnologies, Inc. 19
Asubio Pharmaceuticals, Inc. 20
Acute Spinal Cord Injury – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
BA-210 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Oxycyte - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PN-277 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ATI-355 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Granulocyte Colony Stimulating Factor - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lithium carbonate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Umbilical Cord Blood Mononuclear Cell Transplant - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Umbilical Cord Mesenchymal Stem Cell Transplantation - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SUN-13837 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Lithium Carbonate + Umbilical Cord Blood Mononuclear Cell Transplant - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Brilliant Blue G - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Autologous Schwann Cells - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Acute Spinal Cord Injury Therapeutics – Drug Profile Updates 46
Acute Spinal Cord Injury Therapeutics – Discontinued Products 49
Acute Spinal Cord Injury Therapeutics - Dormant Products 50
Acute Spinal Cord Injury – Product Development Milestones 51
Featured News & Press Releases 51
Apr 23, 2012: Asubio Pharma Initiates Phase II Clinical Study Of SUN13837 In Spinal Cord Injury 51
Mar 14, 2011: StemCells Initiates Neural Stem Cell Trial In Spinal Cord Injury 52
Dec 07, 2010: StemCells Receives Authorization To Conduct Neural Stem Cell Trial In Spinal Cord Injury 52
Sep 20, 2010: Oxygen Biotherapeutics Amends CRADA With US Navy To Include Preclinical Studies Of Oxycyte For Spinal Cord Injury And Hemorrhagic Shock 53
Jun 03, 2010: Study Shows Marked Neuroprotective Effects of Oxycyte Perfluorocarbon Emulsion in a Rat Model of Spinal Cord Injury 53
May 19, 2009: NsGene Granted European Patent Rights To Its Novel Neurotrophic Factor Meteorin For The Treatment Of Neurological Disorders 54
Sep 18, 2008: The European Commission Grants Orphan Drug Designation To Cethrin For The Treatment Of Traumatic Spinal Cord Injury (SCI) 54
Aug 25, 2008: Oxygen Biotherapeutics, Inc. to Meet With FDA to Discuss Proposed Phase II-b Oxycyte Clinical Trial 55
May 12, 2008: Alseres Pharmaceuticals Announces 12 Month Interim Results From The Phase I/IIa Cethrin Clinical Trial In Acute Spinal Cord Injury 56
Apr 24, 2008: Amkor Pharma Completes All Clinical Activities For Its Phase I Study Of Neu2000For Treatment Of Acute Brain Injury 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products Under Development for Acute Spinal Cord Injury, H2 2012 8
Products under Development for Acute Spinal Cord Injury – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Novartis AG, H2 2012 17
Oxygen Biotherapeutics, Inc., H2 2012 18
Proneuron Biotechnologies, Inc., H2 2012 19
Asubio Pharmaceuticals, Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Acute Spinal Cord Injury Therapeutics – Drug Profile Updates 46
Acute Spinal Cord Injury Therapeutics – Discontinued Products 49
Acute Spinal Cord Injury Therapeutics – Dormant Products 50

List of Figures
Number of Products under Development for Acute Spinal Cord Injury, H2 2012 8
Products under Development for Acute Spinal Cord Injury – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos